ARV-825, a novel BET inhibitor using PROTAC technology, has shown promising preclinical efficacy in multiple types of tumors, such as AML, MM, HCC, and liposarcoma (30, 42, 43). The gene discussed is DNER; the disease is acute myeloid leukemia.